The Recombinant Proteins by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Recombinant Proteins Market:
https://www.thebusinessresearchcompany.com/report/recombinant-proteins-global-market-report


According to The Business Research Company’s Recombinant Proteins, The recombinant proteins market size has grown rapidly in recent years. It will grow from $2.12 billion in 2023 to $2.37 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing demand for biopharmaceuticals, rising prevalence of chronic diseases, growing aging population, government initiatives and funding, expanding applications in research and diagnostics..

The recombinant proteins market size is expected to see rapid growth in the next few years. It will grow to $3.79 billion in 2028 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to increased adoption of personalized medicine, rapid expansion of the biotechnology sector, global efforts to address rare diseases, advancements in protein engineering techniques, emerging markets and untapped opportunities.. Major trends in the forecast period include expansion of personalized medicine, rapid growth in the biotechnology sector, demand for therapeutic proteins, emergence of novel therapeutic targets, global focus on vaccine development..

A rising number of regulatory approvals is expected to propel the growth of the recombinant protein market going forward. Regulatory approvals refer to any government or health authority authorization for any research involving human subjects. A rising number of regulatory approvals for recombinant proteins is mandatory for all drugs, which includes the treatment of diabetes, and severe chronic diseases like cancer, cardiovascular diseases, endocrine diseases, and viral diseases. For instance, in January 2022, according to the Centre for Drug Evaluation and Research (CDER), a US-based non-profit organization, 38 (76%) of the 50 medications CDER authorized in 2021 received their first U.S. approval. In comparison to 21 of 53 first-in-class pharmaceuticals (39.5%) in 2020, first-in-class drugs made up 27 of the 50 drugs (54%) approved in 2021, the agency observed. The FDA previously reported that 20 drugs were approved (42%), 19 were approved (32%), and 15 were approved (33%). Therefore, the rising number of regulatory approvals is driving the growth of the recombinant protein market going forward.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=9959&type=smp


The recombinant proteins market covered in this report is segmented –

1) By Product: Antibodies, Cytokines, Immune Checkpoint Protein, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Products
2) By Application: Drug And Discovery Development, Therapeutics, Research, Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institute, Diagnostic Laboratories, Other End Users

Product innovation is the key trend gaining popularity in the recombinant protein market. Major companies operating in the recombinant protein market are focused on developing innovative products to strengthen their position in the market. For instance, in March 2022, ProteoGenix, a France-based biochemistry company launched the XtenCHO Transient CHO Expression System, aimed at improving biologics development. This new system offers several advantages, including ten times higher yields, optimized plasmid stability, and smart protocols with less hands-on time. The XtenCHO™system is designed to be a rapid and cost-effective solution, ideal for both bioanalytical applications and drug development.


Major Players:

Abnova Corporation
Bio-Rad Laboratoroies Inc.
Merck Co. & KGaA
R&D Systems Inc.
Abcam PLC

The recombinant proteins market report table of contents includes:

1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis


Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model